Diligence memo · auto-generated · as of July 2, 2026
Naegis Pharmaceuticals Inc.
Naegis Pharmaceuticals Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Naegis Pharmaceuticals Inc. operates in Biotech / Pharma, based in VANCOUVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Naegis Pharmaceuticals Inc. has raised $351K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $351K on 2024-04-19.
Most recent recorded round closed around 2024-04-19.
Valuation (modeled)modeled
Provath models Naegis Pharmaceuticals Inc. at approximately $1.8M (range $192K–$6.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.86× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era. Within the normal band (86% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.2 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 20% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 15% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., CyMon Bio, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.